| Literature DB >> 34777841 |
Abdullah Alabbas1, Elizabeth Harvey2, Amrit Kirpalani3, Chia Wei Teoh2, Cherry Mammen4, Kristen Pederson5, Rose Nemec2, T Keefe Davis6, Anna Mathew7, Brendan McCormick8, Cheryl A Banks9, Charles H Frenette10, David A Clark11, Deborah Zimmerman8, Elena Qirjazi12, Fabrice Mac-Way13, Hans Vorster14, John E Antonsen15, Joanne E Kappel16, Jennifer M MacRae12, Juliya Hemmett12, Karthik K Tennankore11, Louise M Moist17, Michael Copland18, Michael McCormick19, Rita S Suri20,21, Rajinder S Singh16, Sara N Davison22, Mathieu Lemaire2, Rahul Chanchlani23.
Abstract
PURPOSE OF THE PROGRAM: This article provides guidance on optimizing the management of pediatric patients with end-stage kidney disease (ESKD) who will be or are being treated with any form of home or in-center dialysis during the COVID-19 pandemic. The goals are to provide the best possible care for pediatric patients with ESKD during the pandemic and ensure the health care team's safety. SOURCES OF INFORMATION: The core of these rapid guidelines is derived from the Canadian Society of Nephrology (CSN) consensus recommendations for adult patients recently published in the Canadian Journal of Kidney Health and Disease (CJKHD). We also consulted specific documents from other national and international agencies focused on pediatric kidney health. Additional information was obtained by formal review of the published academic literature relevant to pediatric home or in-center hemodialysis.Entities:
Keywords: clinical practice guidelines; infectious disease; pediatric nephrology; renal replacement therapy
Year: 2021 PMID: 34777841 PMCID: PMC8586166 DOI: 10.1177/20543581211053458
Source DB: PubMed Journal: Can J Kidney Health Dis ISSN: 2054-3581
Case Definitions Use for Patients Without a Confirmed COVID-19 Diagnosis.
| Symptoms + | Symptoms − | |
|---|---|---|
| Exposure + | P1 = Probable | P3 = High Risk |
| Exposure − | P2 = Suspected | P4 = Low Risk |
Note. Exposure is defined as travel outside of Canada, close contact with a person infected or suspected to have COVID-19, or contact with bodily fluids from a person with or suspected to have COVID-19.
Care Pathway for Low Prevalence of COVID-19 in Community.
| P1
| P2
| P3
| P4
| |
|---|---|---|---|---|
| Patient wears mask on entry, | YES | YES | YES | NO |
| “Separated dialysis”
| YES | YES | IF POSSIBLE | NO |
| Droplet/contact PPE
| YES | YES | YES | NO |
| Test for SARS-CoV-2
| YES | WHEN POSSIBLE | NO | NO |
| Shared transportation
| NO | NO | NO | YES |
| Wait in waiting room
| NO | NO | NO | YES |
| Wander in facility | NO | NO | NO | YES |
| Counsel on home isolation | YES | YES | YES | NO |
| Discontinue isolation procedures
| 14 days from exposure | N/A | ||
| Caregiver can accompany patient | YES | YES | YES | YES |
| Visitors can accompany patient
| NO | NO | NO | NO |
Masks for patients
When the prevalence of COVID-19 in the community is high (as determined by public health), all patients should wear masks throughout the treatment, including P4. When prevalence is low, patients who are asymptomatic with no known exposures do not need masks.
Separated Dialysis (Isolation Rooms)
Ideally, P1, P2, and P3 patients should be dialyzed in separate isolation rooms. If this is not possible, maintain droplet/contact precautions by keeping >2 m distance between patients AND using a physical barrier to separate treatment stations, such as plexiglass screens, washable curtains, or disposable plastic sheets.
P1, P2, and P3 patients should NOT be cohorted together, even with patients of the same category. This is to avoid transmission from positive (but not yet confirmed) patients to those who are negative.
Negative pressure ventilation rooms are NOT required for routine dialysis. They are recommended ONLY if an aerosol-generating medical procedure (AGMP) is anticipated, such as high flow oxygen, intubation, or mechanical ventilation. For this reason, we recommend unstable patients are dialyzed in an appropriate location (see 3.1).
Cleaning of the treatment area, machines, and isolation rooms should follow provincial public health agency guidelines.
PPE (Personal Protective Equipment)
Health care workers who care for patients in categories P1, P2, and P3 (ie, exposed or symptomatic) require appropriate PPE for droplet/contact precautions when providing treatment or care within 2 m of the patient. This means a procedure mask, visor, gloves, and gown. Airborne precautions (N95 masks) are NOT required, except for AGMPs. Dialysis is NOT an AGMP.
For patients in category P4: Public health agencies determine whether COVID-19 is highly prevalent in the community. When this is the care, we recommend that health care workers wear a mask and visor for all patients, without changing between patients (ie, they are supplied with 1 or 2 masks for each shift and wear them continuously except for breaks).
Whether to reuse PPE and how to process PPE for reuse should follow provincial public health agency guidelines.
Repeat Testing for P1 and P2 Patients who Are Initially Negative
When there is a high clinical suspicion for COVID-19 and negative nasopharyngeal swab, the test may be repeated. The sensitivity of nasopharyngeal swabs for COVID-19 may be less than 100%. Whether to do more than 2 tests for a single patient should be determined on an individual basis in consultation with local infectious disease specialists.
Transportation
The recommendations in section 2.5 apply here, except that patients who are P1, P2, or P3 should NOT be cohorted together in the same vehicle.
Waiting Room
If feasible, medically stable patients can opt to wait in their car or transport vehicle and be contacted by phone when their treatment spot is ready, to avoid the waiting room.
If the patient must use the waiting room, practice distancing measures with patients separated by at least 2 m. This includes moving chairs to the required separation, or taping chairs that are not to be used, to maintain separation.
Discontinuation of Isolation Procedures
Patients in categories P1 and P2 should remain isolated until they have NO symptoms AND the patient has definitively tested negative for COVID-19.
The duration of isolation may be longer than 14 days for immunocompromised patients—consultation with local infectious disease experts on a case-by-case basis is suggested.
Patients in categories P1 and P3 who have been exposed to outbreaks in a group facility (eg, long-term care facility) should be isolated until at least 14 days AFTER THE OUTBREAK IS CLEARED from their group facility.
Visitors/Caregivers—see section 2.11-2.12.
Care Pathway for High Prevalence of COVID-19 in Community.
| P1
| P2
| P3
| P4
| |
|---|---|---|---|---|
| Patient wears mask on entry, | YES | YES | YES | YES |
| “Separated dialysis”
| YES | YES | IF POSSIBLE | NO |
| Droplet/contact PPE
| YES | YES | YES | Mask and Visor |
| Test for SARS-CoV-2
| YES | YES | NO | NO |
| Shared transportation
| NO | NO | NO | Try to avoid |
| Wait in waiting room
| NO | NO | NO | Try to avoid |
| Wander in facility | NO | NO | NO | NO |
| Counsel on home isolation | YES | YES | YES | Only if recommended for general population |
| Discontinue isolation procedures
| 14 days from exposure | NA | ||
| Caregivers | YES | YES | YES | YES |
| Visitors
| NO | NO | NO | NO |
Masks for patients
When the prevalence of COVID-19 in the community is high (as determined by public health), all patients should wear masks throughout the treatment, including P4. When prevalence is low, patients who are asymptomatic with no known exposures do not need masks.
Separated Dialysis (Isolation Rooms)
Ideally, P1, P2, and P3 patients should be dialyzed in separate isolation rooms. If this is not possible, maintain droplet/contact precautions by keeping >2 m distance between patients AND using a physical barrier to separate treatment stations, such as plexiglass screens, washable curtains, or disposable plastic sheets.
P1, P2, and P3 patients should NOT be cohorted together, even with patients of the same category. This is to avoid transmission from positive (but not yet confirmed) patients to those who are negative.
Negative pressure ventilation rooms are NOT required for routine dialysis. They are recommended ONLY if an aerosol-generating medical procedure (AGMP) is anticipated, such as high flow oxygen, intubation, or mechanical ventilation. For this reason, we recommend unstable patients are dialyzed in an appropriate location (see 3.1).
Cleaning of the treatment area, machines, and isolation rooms should follow provincial public health agency guidelines.
PPE (Personal Protective Equipment)
Health care workers who care for patients in categories P1, P2, and P3 (ie, exposed or symptomatic) require appropriate PPE for droplet/contact precautions when providing treatment or care within 2 m of the patient. This means a procedure mask, visor, gloves, and gown. Airborne precautions (N95 masks) are NOT required, except for AGMPs. Dialysis is NOT an AGMP.
For patients in category P4: Public health agencies determine whether COVID-19 is highly prevalent in the community. When this is the care, we recommend that health care workers wear a mask and visor for all patients, without changing between patients (ie, they are supplied with 1 or 2 masks for each shift and wear them continuously except for breaks).
Whether to reuse PPE and how to process PPE for reuse should follow provincial public health agency guidelines.
Repeat Testing for P1 and P2 Patients who Are Initially Negative
When there is a high clinical suspicion for COVID-19 and negative nasopharyngeal swab, the test may be repeated. The sensitivity of nasopharyngeal swabs for COVID-19 may be less than 100%. Whether to do more than 2 tests for a single patient should be determined on an individual basis in consultation with local infectious disease specialists.
Transportation
The recommendations in section 2.5 apply here, except that patients who are P1, P2, or P3 should NOT be cohorted together in the same vehicle.
Waiting Room
If feasible, medically stable patients can opt to wait in their car or transport vehicle and be contacted by phone when their treatment spot is ready, to avoid the waiting room.
If the patient must use the waiting room, practice distancing measures with patients separated by at least 2 m. This includes moving chairs to the required separation, or taping chairs that are not to be used, to maintain separation.
Discontinuation of Isolation Procedures
Patients in categories P1 and P2 should remain isolated until they have NO symptoms AND the patient has definitively tested negative for COVID-19.
The duration of isolation may be longer than 14 days for immunocompromised patients—consultation with local infectious disease experts on a case-by-case basis is suggested.
Patients in categories P1 and P3 who have been exposed to outbreaks in a group facility (eg, long-term care facility) should be isolated until at least 14 days AFTER THE OUTBREAK IS CLEARED from their group facility.
Visitors/Caregivers—see section 2.11-2.12.
Algorithm to Determine Dialysis Treatment Frequency Priority.
| Priority levels | Parameters | Suggestions |
|---|---|---|
| A | Average interdialytic weight gain | Cannot miss any treatments safely |
| B | Ideally should not miss any treatments
| |
| C | One predialysis K value > 5.5 mEq/L in the last 3 months | Can temporarily miss 1 treatment in a week, but only if necessary.
|
| D | All others | Can temporarily miss 1 treatment in a week, if necessary.
|
Note. Patients should not miss 2 consecutive treatments, and if possible, no more than 2 treatments in 6 weeks.
Patients with serious dialysis access–related issues with decreased blood flows and preexisting poor adequacy or malnutrition should NOT miss any treatments.
Treating physician has the discretion to override this algorithm for individual patients.
Patients for whom hemodialysis frequency has been reduced should be reassessed clinically for uremic symptoms and electrolytes imbalance after each session.
Sodium Polystyrene Sulfonate oral route is more effective than rectal and is preferred.